Optimizing the Treatment of Recurrent/Metastatic SCCHN

Introduction

Current Treatment Guidelines for Recurrent/Metastatic SCCHN

Definition of Patients "Unfit" for Platinum-Based Chemotherapy

Definition of Patients "Unfit" for Platinum-Based Chemotherapy (cont)

Current Treatment Guidelines for Recurrent/Metastatic SCCHN

Definition of First-line Recurrent/Metastatic Disease

In the Recurrent Setting…

State of Art: First-Line Systemic Treatment for Recurrent/Metastatic SCCHN

First-Line Randomized Trials in Recurrent/Metastatic SCCHN

Platinum-Based Chemotherapy Plus Cetuximab: EXTREME Trial

EXTREME Trial: Hazard Ratios for Death

EXTREME Trial: Hazard Ratios for Disease Progression

EXTREME Trial: Grade 3-4 AEs in the Safety Population

EXTREME: A Real Progress but …

Phase 2 Testing: Taxanes and Cetuximab

TPExtreme TRIAL DESIGN

The Challenge of Treating Elderly Patients

Potential Future Directions for Treatment of Elderly Patients with Recurrent/Metastatic SCCHN

Investigational Regimens for Treatment of Elderly Patients with Recurrent/Metastatic SCCHN

Metastatic/Recurrent SCCHN: Treatment Considerations

Current Treatment Guidelines for Recurrent/Metastatic SCCHN

Nivolumab for Recurrent SCCHN*: CheckMate 141

CheckMate 141: Treatment Effect on OS

Efficacy and Safety of Pembrolizumab in Recurrent/Metastatic SCCHN: KEYNOTE-012, a Phase 1b Study

KEYNOTE-012: Response Rates

KEYNOTE-040: Pembrolizumab vs Standard Treatment in Recurrent/Metastatic SCCHN

Recurrent/Metastatic SCCHN: Use of Single-Agent Chemotherapy in the Second-line and Beyond

First-Line Use of Anti-PD-1 Immunotherapy for SCCHN

The Impact of AEs on Treatment Choice

Conclusions

Conclusions (cont)

Abbreviations

Abbreviations (cont)